Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer.

Tajima H, Ohta T, Kitagawa H, Okamoto K, Sakai S, Makino I, Kinoshita J, Furukawa H, Nakamura K, Hayashi H, Oyama K, Inokuchi M, Nakagawara H, Fujita H, Takamura H, Ninomiya I, Fushida S, Tani T, Fujimura T, Ikeda H, Kitamura S.

Exp Ther Med. 2012 May;3(5):787-792. Epub 2012 Feb 13.

2.

A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer.

Tajima H, Kitagawa H, Tsukada T, Nakanuma S, Okamoto K, Sakai S, Makino I, Furukawa H, Nakamura K, Hayashi H, Oyama K, Inokuchi M, Nakagawara H, Miyashita T, Fujita H, Itoh H, Takamura H, Ninomiya I, Fushida S, Fujimura T, Ohta T.

Mol Clin Oncol. 2013 Jul;1(4):768-772. Epub 2013 May 27.

3.

Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.

Motoi F, Ishida K, Fujishima F, Ottomo S, Oikawa M, Okada T, Shimamura H, Takemura S, Ono F, Akada M, Nakagawa K, Katayose Y, Egawa S, Unno M.

Ann Surg Oncol. 2013 Nov;20(12):3794-801. doi: 10.1245/s10434-013-3129-9. Epub 2013 Jul 10.

PMID:
23838925
4.

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).

Heinrich S, Pestalozzi B, Lesurtel M, Berrevoet F, Laurent S, Delpero JR, Raoul JL, Bachellier P, Dufour P, Moehler M, Weber A, Lang H, Rogiers X, Clavien PA.

BMC Cancer. 2011 Aug 10;11:346. doi: 10.1186/1471-2407-11-346.

5.

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.

Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J.

PLoS Med. 2010 Apr 20;7(4):e1000267. doi: 10.1371/journal.pmed.1000267. Review.

6.

Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.

Satoi S, Yanagimoto H, Yamamoto T, Ohe C, Miyasaka C, Uemura Y, Hirooka S, Yamaki S, Ryota H, Michiura T, Inoue K, Matsui Y, Tanigawa N, Kon M.

Surg Today. 2017 Jan;47(1):84-91. Epub 2016 Jun 4.

PMID:
27262676
7.

Neoadjuvant chemotherapy with gemcitabine for pancreatic cancer increases in situ expression of the apoptosis marker M30 and stem cell marker CD44.

Tajima H, Ohta T, Kitagawa H, Okamoto K, Sakai S, Kinoshita J, Makino I, Furukawa H, Hayashi H, Nakamura K, Oyama K, Inokuchi M, Nakagawara H, Fujita H, Takamura H, Ninomiya I, Fushida S, Tani T, Fujimura T, Kitamura S, Ikeda H, Tsuneyama K.

Oncol Lett. 2012 Jun;3(6):1186-1190. Epub 2012 Mar 26.

8.

Neoadjuvant chemotherapy for primary cutaneous/soft tissue angiosarcoma: Determining tumor behavior prior to surgical resection.

Oxenberg J, Khushalani NI, Salerno KE, Attwood K, Kane JM 3rd.

J Surg Oncol. 2015 Jun;111(7):829-33. doi: 10.1002/jso.23891. Epub 2015 Mar 13.

PMID:
25772798
9.

WITHDRAWN: Neoadjuvant chemotherapy versus none for resectable gastric cancer.

Wu AW, Xu GW, Wang HY, Ji JF, Tang JL.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005047. Review.

PMID:
17943834
10.

Neoadjuvant chemotherapy versus none for resectable gastric cancer.

Wu AW, Xu GW, Wang HY, Ji JF, Tang JL.

Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005047. Review. Update in: Cochrane Database Syst Rev. 2007;(4):CD005047.

PMID:
17443566
11.

Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.

Badiyan SN, Olsen JR, Lee AY, Yano M, Menias CO, Khwaja S, Wang-Gillam A, Strasberg SM, Hawkins WG, Linehan DC, Myerson RJ, Parikh PJ.

Am J Clin Oncol. 2016 Feb;39(1):1-7. doi: 10.1097/COC.0000000000000003.

PMID:
26132367
12.

[Examination of resectable and borderline pancreatic cancer treated with neoadjuvant chemoradiation therapy].

Mataki Y, Shinchi H, Maemura K, Kurahara H, Kawasaki Y, Desaki R, Ueno S, Sakoda M, Iino S, Higashi M, Takao S, Natsugoe S.

Gan To Kagaku Ryoho. 2013 Nov;40(12):1637-40. Japanese.

PMID:
24393873
13.

Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma.

Jin C, Yao L, Long J, Fu DL, Yu XJ, Xu J, Yang F, Ni QX.

Chin Med J (Engl). 2009 Feb 5;122(3):284-90.

PMID:
19236805
14.

Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head.

Heinrich S, Pestalozzi BC, Schäfer M, Weber A, Bauerfeind P, Knuth A, Clavien PA.

J Clin Oncol. 2008 May 20;26(15):2526-31. doi: 10.1200/JCO.2007.15.5556.

PMID:
18487569
15.

Impact of Neoadjuvant Chemotherapy Among Patients with Pancreatic Fistula After Gastrectomy for Advanced Gastric Cancer.

Kosaka T, Akiyama H, Makino H, Kimura J, Takagawa R, Ono HA, Kunisaki C, Endo I.

Anticancer Res. 2016 Apr;36(4):1773-7.

PMID:
27069158
16.

Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.

Chatterjee D, Katz MH, Rashid A, Varadhachary GR, Wolff RA, Wang H, Lee JE, Pisters PW, Vauthey JN, Crane C, Gomez HF, Abbruzzese JL, Fleming JB, Wang H.

Cancer. 2012 Jun 15;118(12):3182-90. doi: 10.1002/cncr.26651. Epub 2011 Oct 25.

17.

A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin.

Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, Johnson PJ, Buckels JA, Bramhall SR.

Ann Surg Oncol. 2007 Jul;14(7):2088-96. Epub 2007 Apr 24.

PMID:
17453298
18.

Preoperative Biliary Drainage in Cases of Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Chemotherapy and Surgery.

Tsuboi T, Sasaki T, Serikawa M, Ishii Y, Mouri T, Shimizu A, Kurihara K, Tatsukawa Y, Miyaki E, Kawamura R, Tsushima K, Murakami Y, Uemura K, Chayama K.

Gastroenterol Res Pract. 2016;2016:7968201. doi: 10.1155/2016/7968201. Epub 2016 Jan 6.

19.

Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?

Papalezova KT, Tyler DS, Blazer DG 3rd, Clary BM, Czito BG, Hurwitz HI, Uronis HE, Pappas TN, Willett CG, White RR.

J Surg Oncol. 2012 Jul 1;106(1):111-8. doi: 10.1002/jso.23044. Epub 2012 Feb 6.

PMID:
22311829
20.

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H.

JAMA. 2007 Jan 17;297(3):267-77.

PMID:
17227978

Supplemental Content

Support Center